Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Research progress on selective immunoproteasome inhibitors].

Literature DB >> 31955545

[Research progress on selective immunoproteasome inhibitors].

Limin Kong¹, Jingyi Lu², Huajian Zhu², Jiankang Zhang².

Abstract

Immunoproteasome is associated with various diseases such as hematologic malignancies, inflammatory, autoimmune and central nervous system diseases, and over expression of immunoproteasome is observed in all of these diseases. Immunoproteasome inhibitors can reduce the expression of immunoproteasome by inhibiting the production of related cell-inducing factors and the activity of T lymphocyte for treating related diseases. In order to achieve good efficacy and reduce the toxic effects, key for development of selective immunoproteasome inhibitors is the high selectivity and potent activity of the three active subunits of the proteasome. This review summarizes the structure and functions of immunoproteasome and the associated diseases. Besides, structure, activity and status of selective immunoproteasome inhibitors are also been highlighted.

Entities: Chemical

Mesh：

Substances：

Year: 2019 PMID： 31955545 PMCID： PMC8800774 DOI： 10.3785/j.issn.1008-9292.2019.12.15

Source DB: PubMed Journal: Zhejiang Da Xue Xue Bao Yi Xue Ban ISSN： 1008-9292

Keyword Cloud
References

25 in total

1. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

Authors: J Myung; K B Kim; K Lindsten; N P Dantuma; C M Crews
Journal: Mol Cell Date: 2001-02 Impact factor: 17.970

Review 2. The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis.

Authors: Silke Meiners; John Evankovich; Rama K Mallampalli
Journal: Transl Res Date: 2018-03-29 Impact factor: 7.012

3. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Authors: Claire L Soave; Tracey Guerin; Jinbao Liu; Q Ping Dou
Journal: Cancer Metastasis Rev Date: 2017-12 Impact factor: 9.264

Review 4. The role of the ubiquitin proteasome system in the memory process.

Authors: Philomena Z Y Lip; Marilene Demasi; Diego Bonatto
Journal: Neurochem Int Date: 2016-12-02 Impact factor: 3.921

5. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors: Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal: Blood Date: 2008-12-02 Impact factor: 22.113

[Research progress on selective immunoproteasome inhibitors].

1. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

Review 2. The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis.

3. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Review 4. The role of the ubiquitin proteasome system in the memory process.

5. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

6. LMP2-specific inhibitors: chemical genetic tools for proteasome biology.

7. Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site.

Review 8. Proteasome inhibitors as experimental therapeutics of autoimmune diseases.

9. Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease.

Review 10. The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target.